Santa Reads to You about Medicine

Mario

You better not pout you better not cry you better keep up to date with the latest from the Journal of American Family Practice Pediatrics in Review New England Journal of Medicine Journal of the American Medical Association Journal of the American Geriatric Society and various medical podcasts I like

  1. 6d ago

    Fri 2026/11/13 Friday Consolidation: How Much Is Enough, the Patient on a Biologic, Toddlers, and Asking Before Telling

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! The weekly consolidation for the week of November ninth, covering four episodes. Monday's sweep asked how much is enough, with STREAM on stopping statins after seventy, the OPTIMAL trials on blood pressure targets after stroke and in diabetes, pelacarsen and ziltivekimab, retatrutide for knee osteoarthritis, plozasiran and pancreatitis, long COVID recovery, and three pediatric items. Tuesday was inflammatory bowel disease, part two, the patient on a biologic. Wednesday was the second well-child episode, on toddlers and preschoolers. Thursday was motivational interviewing. Then updates to the menopause episodes and the lipid card, and a retrieval round. Keepers from the week - STREAM: stopping a primary-prevention statin after 70 was "noninferior" but every value in the CI favored continuing; ~1 extra MI, stroke or death per 40 over 2 years, with no gain in symptoms. Default is to continue. - OPTIMAL: SBP target 120 after stroke/TIA (HR 0.79), watch kidneys; in diabetes, 120 didn't clearly beat 140 (HR 0.90, underpowered). Under 130 remains the floor. - Lp(a) and inflammation aren't targets yet: pelacarsen missed in all subgroups; ziltivekimab more infection deaths. - Plozasiran: triglycerides down ~80%, pancreatitis 1 vs 5 per 100 patient-years. - Long COVID: about half improve by 3 years. - Peds: trace pyuria drives overtreatment; direct oral amoxicillin challenge for low-risk penicillin labels. - IBD on a biologic: screen TB, hep B, HCV, HIV first; live vaccines 4+ weeks before; everything nonlive after; colonoscopy surveillance for colitis; skin checks; JAK = CV risk. - Toddlers: no spanking; milk under 24 oz; refer a late talker at 2 (bilingual too); four-sided pool fence; lead questions about spices and greta/azarcon. - MI: ask before you tell; reflect the worry, not the misinformation; rulers. Beats a lecture, not an equal-length alternative; fades. Updates this week - Menopause episodes 1 and 2 (both versions) refreshed: ACOG CPG 13 and the Obstet Gynecol perimenopause toolkit. - Lipid card: when the LDL number and percent disagree; plaque on a cath, CCTA or another CT; incidental CAC grades. Next week: Monday sweep; Tuesday irritable bowel syndrome (tentative); Wednesday well-child part 3, school age. Keywords: weekly consolidation, STREAM, statin discontinuation, deprescribing, OPTIMAL-STROKE, OPTIMAL-DIABETES, blood pressure targets, lipoprotein(a), pelacarsen, ziltivekimab, retatrutide, plozasiran, long COVID, pyuria, penicillin allergy, biologics, vaccines in immunosuppression, surveillance colonoscopy, toddler discipline, cow's milk, late talker, drowning, lead, motivational interviewing, menopause, coronary artery calcium, CME

  2. Nov 12

    Thurs 2026/11/12 Approach: Motivational Interviewing: Eight Conversations

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! Motivational interviewing for the primary care visit, through eight patients with one rule each and then "Behind the rules." The smoker who isn't ready; the drinker who only wants to cut down; the patient who wants to stop a statin; opening a conversation about weight; the parent hesitant about vaccines; missed blood pressure doses; a parent and spanking; and the patient who disagrees with your plan. Then what motivational interviewing actually is, and an honest look at the evidence, from Rubak's twenty oh five meta-analysis in the British Journal of General Practice through Lundahl's twenty thirteen review, the twenty twenty-three Cochrane review on substance use, and the twenty twenty-two to twenty twenty-four meta-analyses on weight, physical activity and blood pressure. It beats no intervention, it rarely beats an equally long alternative, and it fades. Companion card: https://claude.ai/artifact/Ra1eCrre5kGfK272wYQ4k9 Eight patients, eight rules 1. Smoker not ready: ask permission, then ask what they know and want before telling. Resist the righting reflex. 2. Drinker who wants to cut down: reduction is a legitimate goal; offer medication anyway (naltrexone, acamprosate). Expect several conversations. 3. Wants to stop a statin: find out why first, reflect the value underneath, then share numbers with ask-tell-ask. Accept, document, revisit. 4. Weight: ask permission and explore their goals (5 A's). MI opens the door; the treatment is a program or medication. 5. Vaccine-hesitant parent: strong presumptive recommendation first. If they hesitate, pivot to a brief MI conversation. Reflect the worry, not the misinformation. 6. Missed BP doses: normalize, ask, then use importance and confidence rulers (0 to 10). Work on whichever is lower. 7. Parent who spanks: evoke the parent's own goal for the child, then offer alternatives. 8. Patient who disagrees: validate the emotion, not the request. Be clear about scope; agree to revisit; notice your own reaction. Evidence in one line: better than no intervention or a pamphlet, small effects, usually no better than an equally long alternative, fades by a year. Sources - Rubak et al., Br J Gen Pract 2005 (72 RCTs) - Lundahl et al., Patient Educ Couns 2013 (48 RCTs in medical care) - Schwenker et al., Cochrane 2023, substance use (93 studies) - Michalopoulou et al., Ann Intern Med 2022 (weight, 46 RCTs) - Zhu et al., BMJ 2024 (physical activity, 97 RCTs) - Huang et al., Patient Educ Couns 2023 (hypertension, 11 RCTs) - Bischof et al., Dtsch Arztebl Int 2021 (narrative review) - ACP 2026: Team-Based Approaches to Vaccine Uptake (Hopkins); Approach to the Patient Who Disagrees With Your Care (Stonington); obesity and hospital addiction sessions - Sege and Siegel, AAP Effective Discipline, Pediatrics 2018 Keywords: motivational interviewing, behavior change, OARS, change talk, sustain talk, righting reflex, elicit-provide-elicit, ask-tell-ask, importance ruler, confidence ruler, five A's, smoking cessation, alcohol, naltrexone, statin hesitancy, obesity counseling, vaccine hesitancy, presumptive recommendation, medication adherence, hypertension, discipline, shared decision making, difficult conversations, countertransference, boundaries, CME

  3. Nov 11

    Wed 2026/11/11 Peds: Well-Child Care, Part Two: Toddlers and Preschoolers

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! The second of three well-child episodes, on toddlers and preschoolers, through eight families and the question each one asks, then "Behind the rules." A two-year-old's tantrums and whether a swat is all right; a picky eater drinking a quart of milk a day; toilet training, refusal and regression; a bilingual two-year-old with twenty words; tablets and the AAP's new digital ecosystems policy; bedtime battles and melatonin; a new apartment with a pool; and lead, including imported spices, pottery and folk remedies. Built on the AAP policies on discipline, digital media and drowning prevention, the AAP iron deficiency report, AFP reviews of early childhood concerns and speech delay, and Pediatrics in Review on toilet training, autism and lead. Companion card: https://claude.ai/artifact/GHoAErVcDGTjQ4jHarDpX5 Eight families, eight rules 1. Discipline: no hitting, no yelling or shaming. Praise what you want, ignore minor misbehavior, brief time-out for the rest. Tantrums are normal at 1-4. 2. Milk under 24 oz a day (16-24 is a good target); offer iron-rich foods; a new food may take up to 15 tries. No pressure, no punishment at meals. 3. Toilet training: start after 18 months, when the child is ready. Toilet refusal: diaper back, treat constipation. Regression: check constipation, UTI, new diabetes. 4. Under 50 words or no two-word phrases at 24 months: refer to speech and audiology now, not later. Same criteria for bilingual children. Under 3: early intervention (self-referral). M-CHAT-R/F at 18 and 24 months. 5. Screens: content and co-viewing over minutes; no devices to calm a tantrum; no screens before bed. If a family wants a number, under 1 hour a day. 6. Sleep: 11-14 hours at 1-2 years, 10-13 at 3-5 including naps. Behavioral approaches first; ask about melatonin and diphenhydramine. Snoring: think apnea. 7. Drowning is the leading cause of death at 1-4. Four-sided pool fencing with a self-closing gate, constant supervision, swim lessons from age 1, empty buckets. 8. Lead: test at 12 and 24 months. Ask about imported spices, candies, glazed pottery, and folk remedies (greta, azarcon). Confirm capillary results with a venous sample. Sources - Sege and Siegel, AAP Effective Discipline, Pediatrics 2018;142:e20183112 - Powers et al., AAP iron deficiency clinical report, Pediatrics 2026; Bryce et al., Early Childhood Concerns, Am Fam Physician 2025;111:31-36 - Johnson and Burman, Toilet Training (In Brief), Pediatr Rev 2026;47:290 - Rupert et al., Speech and Language Delay, Am Fam Physician 2023;108:181-188; Long and Register-Brown, ASD, Pediatr Rev 2021 - Munzer et al., AAP Digital Ecosystems policy, Pediatrics 2026 - Shenoi et al., AAP Prevention of Drowning, Pediatrics 2026;158 - Markowitz, Lead Poisoning: An Update, Pediatr Rev 2021;42:302 Keywords: well-child care, toddler, preschool, anticipatory guidance, tantrums, discipline, corporal punishment, spanking, time-out, picky eating, cow's milk, iron deficiency, toilet training, toilet refusal, constipation, speech delay, late talker, bilingual, early intervention, autism screening, M-CHAT-R/F, screen time, digital media, sleep, melatonin, drowning, pool fencing, swim lessons, lead poisoning, folk remedies, pediatrics, CME

  4. Nov 10

    Tues 2026/11/10 Approach: Inflammatory Bowel Disease, Part Two: The Patient on a Biologic

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! Inflammatory bowel disease, part two, the primary care side of a patient on advanced therapy, through eight patients with one rule each and then "Behind the rules." The checklist before a first biologic dose; which vaccines to give once immunosuppressed, and who counts as immunosuppressed; why colitis means surveillance colonoscopy and not a stool test; skin, cervical and anal cancer screening on thiopurines and anti-TNF drugs; bone density, vitamin D, iron and B12; NSAIDs, acetaminophen and back pain; pregnancy planning on a biologic; and cardiovascular risk and mood on a JAK inhibitor. Built on the August twenty twenty-six Annals In the Clinic review, the twenty twenty-five ACG ulcerative colitis and Crohn guidelines, and three ACP twenty twenty-six sessions. Companion card: https://claude.ai/artifact/5dYkLgjbTQmnKSaUN9ZbRS Eight patients, eight rules 1. Before the first dose: IGRA or TST; HBsAg, anti-HBc, anti-HBs; HCV and HIV per USPSTF; document varicella and MMR. Live vaccines at least 4 weeks before immunosuppression. 2. Once immunosuppressed: everything nonlive. Shingrix (any age 19+), PCV20 or PCV21, inactivated flu (high-dose on anti-TNF), COVID (extra dose), hep A, hep B (Heplisav-B), HPV, RSV 50-74 if immunosuppressed. Immunosuppressed = prednisone 20 mg+ for 14 days+, thiopurines, methotrexate, biologics, JAK, S1P. Not mesalamine, standard budesonide, rectal therapy. 3. Colitis means surveillance colonoscopy, starting 8-10 years after symptom onset (at diagnosis with PSC), every 1-3 years. Stool tests don't substitute. 4. On thiopurines, anti-TNF or JAK: annual skin exam and sun protection; cervical screening per USPSTF, consider shorter intervals; perianal Crohn raises anal cancer risk. 5. DEXA with 2+ steroid courses, BMI under 20, smoking, postmenopause or hypogonadism, at any age. Annual vitamin D and ferritin/TSAT; B12 with ileal disease. IV iron if Hb under 10 with active disease; parenteral B12. 6. Acetaminophen first; NSAIDs with caution, and none in a severe flare. Inflammatory back pain in IBD: think axial spondyloarthritis. 7. Pregnancy: remission 3-6 months first. Keep biologics, thiopurines and 5-ASA. Stop methotrexate, JAK and S1P modulators 3+ months before conception. 8. IBD is a cardiovascular risk enhancer; JAK inhibitors: lipids, caution in older smokers. Screen yearly for depression and anxiety. Sources - Park and Singh, In the Clinic: Inflammatory Bowel Disease, Ann Intern Med Aug 2026 (health care maintenance) - Farraye et al., ACG preventive care in IBD, Am J Gastroenterol 2025 (via In the Clinic) - Rubin et al., ACG UC guideline, and Lichtenstein et al., ACG Crohn guideline, Am J Gastroenterol 2025 - ACP 2026: Primary Care of the Solid Organ Transplant Recipient; Iron Deficiency Anemia; Update in Rheumatology Keywords: inflammatory bowel disease, Crohn disease, ulcerative colitis, biologics, anti-TNF, infliximab, adalimumab, vedolizumab, JAK inhibitors, tofacitinib, thiopurines, health care maintenance, tuberculosis screening, hepatitis B reactivation, vaccines, Shingrix, PCV20, Heplisav-B, live vaccines, colorectal cancer surveillance, primary sclerosing cholangitis, skin cancer, cervical cancer screening, bone density, iron deficiency, vitamin B12, NSAIDs, pregnancy, depression, CME

  5. Nov 9

    Mon 2026/11/09 Monday Sweep: Stopping Statins After Seventy, How Low to Go on Blood Pressure, and How Much Is Enough

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! The American Heart Association late-breakers landed in the New England Journal this weekend, and nearly every one asks the same question, "how much is enough?" The sweep leads with STREAM, a trial of stopping statins in adults over seventy without heart disease, which met its noninferiority goal while causing more heart attacks and strokes and improving nothing measurable, and pairs it with STAREE from two weeks ago. Then OPTIMAL-STROKE and OPTIMAL-DIABETES, twin Brazilian trials of a systolic target under one twenty, which helped after stroke and didn't clearly help in diabetes. Then the full papers for pelacarsen and ziltivekimab, retatrutide for knee osteoarthritis, plozasiran and pancreatitis, long COVID recovery in RECOVER, and three pediatric items on low-level pyuria, penicillin delabeling and fathers in infant feeding. It closes with pointers and three questions. Sources (full text: first three items; others abstract level) - STREAM (Rodondi et al.), NEJM 2026, doi 10.1056/NEJMoa2606634 - OPTIMAL-STROKE (Sampaio Silva), doi 10.1056/NEJMoa2612924; OPTIMAL-DIABETES (Santo), doi 10.1056/NEJMoa2612922 - Lp(a)HORIZON (Cho), doi 10.1056/NEJMoa2610159; NEJM Evidence extended analyses, EVIDoa2600373; ZEUS (Ridker), doi 10.1056/NEJMoa2612126 - TRIUMPH-4 and TRIUMPH-1-OA, doi 10.1056/NEJMoa2610676 - SHASTA-3 and -4, NEJM 2026;395:1805-17, doi 10.1056/NEJMoa2610014 - RECOVER-Adult (Reeder et al.), Annals, doi 10.7326/ANNALS-25-05275 - Wattier et al., Pediatrics, doi 10.1542/peds.2026-077011; Larson et al., doi 10.1542/peds.2026-077964; Whooten et al., doi 10.1542/peds.2025-075313 - ACP 2026: Stroke, Common Challenges in the Hospital (Jennifer Rasmussen); Challenges in Geriatric Medication Management - Background: BPROAD (NEJM 2025), ACCORD-BP, SPRINT, 2025 ACC/AHA BP guideline STREAM at a glance - 1,880 adults 70+ (mean 77.5), on a statin for primary prevention, 2+ chronic conditions; open label - Stop vs continue; primary: nonfatal MI, nonfatal ischemic stroke, or death - Event-free time at 2 y: -2.0 weeks with stopping (CI -3.7 to -0.3); margin -5.2 weeks - 2-y events 10.7% vs 8.2% (NNH ~40); full follow-up HR 1.38 (1.05-1.81) - MI 15 vs 6; ischemic stroke 21 vs 8; deaths 92 vs 75; QoL, pain, falls no different - DSMB advised the stop group to discuss restarting OPTIMAL trials at a glance (Brazil, open label, SBP 120 vs 140) - Stroke/TIA: 4,368 pts; SBP 122 vs 135; 10.9% vs 13.5%, HR 0.79 (0.67-0.94); renal 3.9% vs 2.2%, HR 1.76 - Diabetes: 9,476 pts, 62% women; SBP 122 vs 135; 6.0% vs 6.7%, HR 0.90 (0.77-1.06); kidney 5.7% vs 3.7% - BPROAD (China, diabetes): 12,821 pts; HR 0.79 (0.69-0.90) Keywords: evidence sweep, STREAM, statin discontinuation, deprescribing, older adults, noninferiority, restricted mean survival time, STAREE, OPTIMAL-STROKE, OPTIMAL-DIABETES, intensive blood pressure, SPRINT, ACCORD, BPROAD, Lp(a)HORIZON, pelacarsen, ZEUS, ziltivekimab, retatrutide, knee osteoarthritis, plozasiran, pancreatitis, long COVID, pyuria, penicillin allergy, CME

  6. Nov 6

    Fri 11/06/2026 Friday Consolidation: Finding Versus Fixing, Plaque Without an Event, the First Year, and Bloody Diarrhea

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! The weekly consolidation for the week of November second, covering four episodes. Monday's sweep asked whether finding more, or fixing more, actually helped the patient, with ASPIRED on patch monitoring after syncope, CHAMPION-AF on left atrial appendage closure, CREST-H on carotid revascularization and cognition, and intrauterine numbing for IUD placement. Tuesday was chronic coronary disease, including who counts as having it. Wednesday was the first well-child episode, on infancy. Thursday was inflammatory bowel disease, part one. Then corrections, a check of the new ACOG menopause guideline against our two menopause episodes, and a retrieval round. Keepers from the week - Patch monitoring after unexplained syncope finds more arrhythmias sooner but didn't reduce repeat fainting (ASPIRED). - Watchman vs DOAC: much less nonprocedural bleeding, possibly more ischemic strokes (CHAMPION-AF; industry-funded, generous margin). - Plaque on a scan is coronary disease; the amount sets the LDL goal (CAC 1-99 100; 100-999 70; 1000+ 55). - Stents treat symptoms in stable disease; beta-blocker after an old MI with normal EF can usually come off, but ABYSS shows stopping isn't free. - Infancy: back, alone, flat, room-share, never a couch; iron by 4 months if exclusively breastfed; CBC + ferritin at 9-12 (breastfed) or 15-18 months (formula); peanut early; RSV by one route. - IBD: C. diff first; calprotectin for IBS vs IBD; 6+ bloody stools with systemic signs = admit; mesalamine for UC, not Crohn; steroids are a bridge. Corrections - Monday sweep (fixed in the posted file): CHAMPION-AF ischemic stroke or embolism 45 vs 29 patients (not 27); "2% serious procedural complications" replaced with pericardial effusion needing intervention 0.7%; ASPIRED randomization was within 72 hours. - Chronic coronary disease: ABYSS now verified (NEJM 2024; 3,698 patients; stopping beta-blocker not noninferior, 23.8% vs 21.1%). - Infancy: LEAP numbers verified (13.7% vs 1.9% peanut allergy at 5 years). ACOG Clinical Practice Guideline 13 (Nov 2026) vs our menopause episodes - Agrees: hormone therapy first line for hot flashes (strong) and for hot-flash-related sleep problems (strong); start before 60 or within 10 years; reassess at 3 months then yearly; no automatic stop date. - Differs in emphasis: neurokinin antagonists (fezolinetant, elinzanetant) get a strong recommendation alongside SSRIs/SNRIs; gabapentin is a conditional second-line. - New details: hormone therapy not recommended for depressive symptoms (insufficient evidence); CBT, mindfulness, exercise, hypnosis, acupuncture suggested; clonidine not recommended; elinzanetant LFTs at baseline and 3 months. Keywords: weekly consolidation, ASPIRED, syncope, CHAMPION-AF, left atrial appendage closure, CREST-H, mepivacaine, IUD, chronic coronary disease, subclinical atherosclerosis, coronary artery calcium, beta-blockers, ABYSS, stents, safe sleep, infant iron, ferritin, peanut introduction, RSV, nirsevimab, milestones, hepatitis B birth dose, ulcerative colitis, Crohn disease, fecal calprotectin, acute severe ulcerative colitis, mesalamine, ACOG menopause guideline, fezolinetant, elinzanetant, CME

  7. Nov 5

    Thurs 2026/11/05 Approach: Inflammatory Bowel Disease, Part One: Eight Patients, Eight Rules

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! Inflammatory bowel disease, part one, through eight patients with one rule each, then a "Behind the rules" section with the numbers. A twenty-eight-year-old with three weeks of bloody diarrhea, and why the first test is a stool study; separating IBD from irritable bowel with fecal calprotectin; the clues that point to Crohn disease, from perianal disease to iron deficiency; when bloody diarrhea means admission, and the hospital checklist for acute severe colitis; mesalamine for mild ulcerative colitis and why rectal therapy matters; why mesalamine doesn't work in Crohn disease and steroids are only a bridge; treating to a target beyond symptoms; and what primary care does before a biologic starts. Built on the twenty twenty-five ACG guidelines for ulcerative colitis and Crohn disease, the AFP review of Crohn disease, and the Annals In the Clinic review of IBD. Part two covers the primary care role in a patient already on advanced therapy. Companion card: https://claude.ai/artifact/N8X4TLDqGpPMyTgL3AucGE Eight patients, eight rules 1. Bloody diarrhea: stool C. difficile (strong) and enteric pathogens first, then colonoscopy with ileal intubation and biopsies. No IBD serologies (strong recommendation against). 2. IBS or IBD? Fecal calprotectin decides who needs colonoscopy (NPV ~99.6%). Red flags: blood, nocturnal stools, weight loss, anemia, fever, family history, onset over ~45-50. 3. Crohn clues: perianal disease, mouth ulcers, iron deficiency or B12 deficiency, growth faltering, eye/skin/joint findings (precede diagnosis in up to 26%). Ileocolonoscopy plus CT or MR enterography. 4. Admit when bloody stools are 6+ a day with fever, tachycardia, anemia or high ESR/CRP. Hospital: C. diff test, pharmacologic VTE prophylaxis, IV methylprednisolone 60 mg/day, no routine antibiotics or TPN; no response by day 3 = infliximab or cyclosporine. 5. Mild UC: mesalamine. Proctitis: 1 g suppository daily. Left-sided: enema 1 g + oral 2 g+. Extensive: oral 2-2.4 g is as good as 4.8 g for mild disease; once daily is fine. 6. Crohn disease: mesalamine doesn't work. Mild ileal disease: budesonide up to 3 months. Moderate-severe: biologic early. Steroids are a bridge, stopped within 3 months, never maintenance. 7. Treat to a target: endoscopic improvement, not just symptoms. Recheck calprotectin to monitor. 8. Before a biologic: TB and hepatitis B screening, vaccines (no live vaccines once immunosuppressed), stop smoking (Crohn). Sources - Rubin et al., ACG Clinical Guideline Update: Ulcerative Colitis in Adults, Am J Gastroenterol 2025;120:1187-1224 - Lichtenstein et al., ACG Clinical Guideline: Management of Crohn's Disease in Adults, Am J Gastroenterol 2025;120:1225- - Veauthier et al., Crohn's Disease: Diagnosis and Management, Am Fam Physician 2026;114:139-147 - Park and Singh, In the Clinic: Inflammatory Bowel Disease, Ann Intern Med Aug 2026 - ACP 2026: searched Update in Gastroenterology, Clinical Pearls GI, GI for the Inpatient Clinician; no substantive IBD content Keywords: inflammatory bowel disease, ulcerative colitis, Crohn disease, bloody diarrhea, Clostridioides difficile, fecal calprotectin, irritable bowel syndrome, perianal fistula, extraintestinal manifestations, iron deficiency anemia, Truelove and Witts, acute severe ulcerative colitis, methylprednisolone, infliximab, cyclosporine, VTE prophylaxis, mesalamine, 5-ASA, budesonide, corticosteroids, biologics, treat to target, endoscopic healing, smoking cessation, tuberculosis screening, hepatitis B, CME

  8. Nov 4

    Wed 2026/11/04 Peds: Well-Child Care, Part One: Infancy

    Got something to say to this podcast? Send a voicemail, and you might hear yourself on the next episode! The first of three well-child episodes, on infancy, through eight families and the question each one asks, then a "Behind the rules" section with the numbers. A breastfeeding mother who plans to bring the baby into bed; a six-week-old who cries every evening; a two-month-old whose head always turns one way; vitamin D, iron and when to screen for anemia under the new AAP report; starting solids and peanut; an October baby whose mother had the RSV vaccine; the nine-month developmental screen and the revised milestones; and the hepatitis B birth dose and the AAP immunization schedule. Built on the AAP safe sleep policy, the twenty twenty-six AAP reports on iron deficiency and RSV, a new systematic review on excessive crying, a randomized trial of maternal RSV vaccine with infant nirsevimab, the NIAID peanut guidelines, the CDC and AAP milestone revision, and Pediatrics in Review. Companion card: https://claude.ai/artifact/KwqZnLcrEqXgHMcQcTQcJK Eight families, eight rules 1. Sleep: back, alone, flat, in the parents' room (ideally 6 months); never a couch or armchair. Bed sharing is not recommended; under 4 months it carries 5-10x the risk. 2. Crying: peaks around 6 weeks, eases by 3-4 months. Rule out red flags, then support the parent; it's OK to put the baby down safely and step away. 3. Head always turned one way: check neck rotation at birth and at every early visit; refer to PT early (best before 1 month). Tummy time 15-30 min/day by 7 weeks. 4. Vitamin D 400 IU daily for breastfed infants; iron 1 mg/kg/day by 4 months if exclusively breastfed (or iron-rich foods from 6 months). No cow's milk before 12 months. Screen CBC + ferritin at 9-12 months (breastfed) or 15-18 months (formula). 5. Peanut early: severe eczema or egg allergy, 4-6 months (consider testing first); mild-moderate eczema, around 6 months at home; no eczema, with other solids. About 2 g peanut protein first, then 6-7 g a week. 6. RSV: one product, not both. Mother vaccinated 14+ days before birth: no infant antibody. Otherwise nirsevimab or clesrovimab, ideally in the first week. 7. Development: milestones now reflect what 75% of children do (don't wait and see). Standardized screen at 9, 18, 30 months; autism at 18 and 24. Refer to early intervention directly. 8. Hepatitis B within 24 hours of birth; follow the AAP schedule (which recommends COVID vaccine for all children 6-23 months). Sources - Moon et al., AAP safe sleep policy, Pediatrics 2022;150:e2022057990; Carlin and Moon, Pediatr Rev 2024 (SUID) - Bilgin et al., Interventions for excessive crying, Pediatrics 2026;158:e2025075063 - Demharter et al., Torticollis, Pediatr Rev Nov 2026 - Powers et al., AAP iron deficiency clinical report, Pediatrics 2026 - Togias et al., NIAID peanut addendum, J Allergy Clin Immunol 2017 - AAP RSV policy statement, Pediatrics 2026;158:e2026079047; Rostad et al., Pediatrics 2026;157:e2025075223 - Zubler et al., Pediatrics 2022;149:e2021052138; Lipkin and Macias, Pediatrics 2020;145:e20193449 - AAP 2026 child and adolescent immunization schedule Keywords: well-child care, infancy, safe sleep, SIDS, bed sharing, room sharing, colic, excessive crying, period of PURPLE crying, congenital muscular torticollis, plagiocephaly, tummy time, vitamin D, iron deficiency, ferritin, peanut allergy prevention, LEAP, early allergen introduction, RSV, nirsevimab, clesrovimab, maternal RSV vaccine, developmental surveillance, milestones, developmental screening, hepatitis B birth dose, immunization schedule, pediatrics, CME

About

You better not pout you better not cry you better keep up to date with the latest from the Journal of American Family Practice Pediatrics in Review New England Journal of Medicine Journal of the American Medical Association Journal of the American Geriatric Society and various medical podcasts I like